Menopause and metabolic dysfunction-associated steatotic liver disease
Maturitas · 2024
DOI: 10.1016/j.maturitas.2024.108024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Maturitas, 2024. Verfasst von Stergios A Polyzos und 1 weiteren Autor:innen. Beteiligte Einrichtung: First Laboratory of Pharmacology, Medical School, Aristotle University of Thessaloniki, Campus of Aristotle University, 54124 Thessaloniki, Greece. E…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Menopause, Estrogen Replacement Therapy. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Nonalcoholic fatty liver disease, recently proposed to be renamed metabolic dysfunction-associated steatotic liver disease, is a highly prevalent disease (25-30 % of the global general population) whose prevalence increases after menopause. Apart from the rates of simple steatosis, the severity of the disease (e.g., hepatic fibrosis) increases after menopause. Menopause is associated with higher abdominal adiposity and dysmetabolism of carbohydrate and lipid metabolism, which may contribute to the development and severity of metabolic dysfunction-associated steatotic liver disease and the higher cardiovascular risk observed after menopause. The association between menopause and metabolic dysfunction-associated steatotic liver disease renders menopausal hormone therapy an appealing way to reverse hepatic disease in parallel with the benefits of menopausal hormone therapy in other tissues. In this regard, most animal studies have shown a beneficial effect of estrogens on metabolic dysfunction-associated steatotic liver disease. Still, clinical studies are few, and their data are conflicting. The effect of menopausal hormone therapy on metabolic dysfunction-associated steatotic liver disease may be distinct among estrogen monotherapies and the combinations of estrogens and progestogens. It may also depend on the type of progestogen and the route of administration. However, more studies specifically designed for these aims are needed to draw secure conclusions. This review summarizes the data related to the association between menopause and metabolic dysfunction-associated steatotic liver disease, as well as between menopausal hormone therapy and metabolic dysfunction-associated steatotic liver disease, with a special focus on clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Laboratory of Pharmacology, Medical School, Aristotle University of Thessaloniki, Campus of Aristotle University, 54124 Thessaloniki, Greece. Electronic address: spolyzos@auth.gr.
- Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Ring Road, 56403 Thessaloniki, Greece. Electronic address: dgg@auth.gr.
Zitieren
APA
Polyzos, S. A., & Goulis, D. G. (2024). Menopause and metabolic dysfunction-associated steatotic liver disease. Maturitas. https://doi.org/10.1016/j.maturitas.2024.108024
Vancouver
Polyzos SA, Goulis DG. Menopause and metabolic dysfunction-associated steatotic liver disease. Maturitas. 2024. doi:10.1016/j.maturitas.2024.108024
BibTeX
@article{Polyzos2024,
author = {Polyzos, Stergios A and Goulis, Dimitrios G},
title = {Menopause and metabolic dysfunction-associated steatotic liver disease},
journal = {Maturitas},
year = {2024},
doi = {10.1016/j.maturitas.2024.108024}
}
EUVIMED